|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive Transfer of Interleukin-21-stimulated Human CD8+ T Memory Stem Cells Efficiently Inhibits Tumor Growth.
|
29864078 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Vaccination with irradiated cells overexpressing GM-CSF or IL-21 alone significantly inhibited tumor growth and led to significantly more CD4<sup>+</sup> CD8<sup>+</sup> T cells and fewer CD4<sup>+</sup> Foxp3<sup>+</sup> T cells in the spleen and xenograft.
|
31467912 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, our data further demonstrate that formation of this cytotoxic subset was critically dependent on CD4<sup>+</sup> T cell help via interleukin-21 (IL-21) and that exploitation of this developmental pathway could be used therapeutically to enhance the killer function of CD8<sup>+</sup> T cells infiltrated into the tumor.
|
31810883 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that the frequency of IL-21-producing CD8+CXCR5+ T cells was higher in HCC tumor tissue than in peritumoral tissue or peripheral blood from the same patients or in blood from healthy donors.
|
31663864 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin 21 (IL-21), which belongs to the common γ-chain (γc) family, is a novel tumor suppressor that has been shown to affect T-cell proliferation, survival and function.
|
29616746 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, we showed that the transcriptional levels of IL-21 in the peritumoral region and IL-21R within the tumor are associated with survival and recurrence of HCC patients.
|
30524894 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors.
|
29683891 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Given the effects of the checkpoint blockade and rIL21 combination on NK cells infiltrating into MHC class I-deficient tumors, we suggest that the efficacy of checkpoint blockade can be enhanced through the administration of IL21 for advanced cancer patients with MHC class I-low/deficient tumors.<i></i>.
|
29615398 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-21-secreting hUCMSCs combined with miR-200c inhibit tumor growth and metastasis via repression of Wnt/β-catenin signaling and epithelial-mesenchymal transition in epithelial ovarian cancer.
|
29692616 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Double immunofluorescence observations confirmed that IL-21 positive cells were mostly natural killer cells and T lymphocytes in the tumor stroma.
|
28887120 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The purpose of this study is to evaluate the efficacy of <i>ex vivo</i> expanded human NK cells in controlling primary and metastatic ES tumor growth <i>in vitro</i> and <i>in vivo.</i> Using membrane-bound IL-21 containing K562 (K562-mbIL-21) expansion platform, we were able to obtain sufficient numbers of expanded NK (eNK) cells that display favorable activation phenotypes and inflammatory cytokine secretion, along with a strong <i>in vitro</i> cytotoxic effect against ES.
|
28507811 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the recovery of NK-cell function by IL-21 is critical for the anti-tumour effects of the vaccine against advanced tumours.
|
28585539 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, when present in the tumor microenvironment, IL-21 might negatively impact γδ T cell anti-tumor functions.
|
29296543 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DsNKG2D-IL-21 gene nanoparticles accumulated in tumor tissues after being intravenously injected for ~4-24 h. Treatment of dsNKG2D-IL-21 gene nanoparticles also retarded tumor growth and elongated the life span of tumor-bearing mice by activating NK and T cells in vivo.
|
28450784 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo αCD20-IL-21 therapy resulted in a significant tumor control in the rituximab-resistant A20-huCD20 tumors.
|
28137826 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated the efficacy of immune-modulatory interleukin-21 (IL-21) combined with checkpoint blockade in several syngeneic mouse tumor models.
|
29296539 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Following azoxymethane and dextran sulfate sodium intervention, miR-21-knockout mice showed reduced expression of proinflammatory and procarcinogenic cytokines (interleukin (IL) 6, IL-23, IL-17A and IL-21) and a decrease in the size and number of tumours compared with the control mouse group.
|
25994220 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we found that administering recombinant IL21 in combination with anti-ErbB2 therapy was therapeutic against primary tumors and experimental metastases in mice.
|
26744522 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, the administration of IL-15 and IL-21 in combination with CART cells in vivo increased their tumor killing capacity.
|
27409425 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-21 can exert additional protective functions for the host as it promotes cytotoxic responses against tumors and viruses.
|
25162763 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intratumoral injection of DCs, engineered to express IL-12, IL-21, or IFN-α, showed potent therapeutic effect against established tumor.
|
22223258 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To address the mechanism of UBMC-MSC-IL-21 against ovarian cancer, the expression of IL-21, natural killer glucoprotein 2 domain and major histocompatibility complex class I chain-related molecules A/B were detected in UBMC-MSC-IL-21 and in the tumor sites.
|
22172102 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Administration of a neutralizing IL-21 antibody to WT mice after the last DSS cycle decreased the colonic T cell infiltrate and the production of IL-6 and IL-17A and reduced the number of tumors.
|
21987656 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, IL-21 promotes tumor regression and prolongs survival of mice harboring xenograft DLBCL tumors.
|
19965678 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-21 was also consistently expressed in ALK(+)ALCL tumors, although its mRNA was detectable in only one of three cell lines tested.
|
19608866 |
2009 |